Opinion
Video
Author(s):
The expert panel underscores the critical importance of rapid diagnostic testing and identification of driver alterations to optimize patient outcomes, given the often-narrow therapeutic window for chemotherapy and targeted therapies.
Crofelemer Misses Diarrhea End Point in Patients With Solid Tumors Receiving Targeted Therapy
Dietrich and Shiller Dive Into the Importance of Oncology Reflex Testing
Frontline Osimertinib Plus Chemo Wins Canadian Approval for EGFR+ Advanced NSCLC
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Best Practices in Treating Early-Stage NSCLC
European Commission Approves Osimertinib Plus Chemo for Advanced EGFR+ NSCLC
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Dr Sabari on Barriers to Biomarker Testing in NSCLC
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC
Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC